Numine-NT Tablet is a combination pharmaceutical formulation containing Pregabalin 75 mg and Nortriptyline 10 mg, indicated for the management of neuropathic pain and certain chronic pain conditions. Pregabalin, an anticonvulsant and neuropathic pain agent, binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, thereby modulating neurotransmitter release and reducing neuronal excitability. Nortriptyline, a tricyclic antidepressant, inhibits the reuptake of norepinephrine and serotonin, enhancing descending inhibitory pain pathways and providing additional analgesic effects. This synergistic combination is particularly effective in alleviating symptoms associated with diabetic neuropathy, postherpetic neuralgia, and other neuropathic pain syndromes. Numine-NT is administered orally, with dosage individualized based on patient response and tolerability. Common adverse effects may include dizziness, somnolence, dry mouth, constipation, and potential cardiovascular effects such as orthostatic hypotension. Caution is advised in patients with a history of cardiac disorders, glaucoma, or seizure disorders. It is contraindicated in patients with hypersensitivity to either component. Regular monitoring and dose adjustments are recommended to optimize therapeutic outcomes while minimizing side effects. Numine-NT should be used under strict medical supervision, considering potential drug interactions and patient-specific factors.